DNA binding of the transcription activator protein MelR from Escherichia coli and its C-terminal domain

Victoria J. Howard, Tamara A. Belyaeva, Stephen J. W. Busby and Eva I. Hyde*

School of Biosciences, The University of Birmingham, Edgbaston, Birmingham B15 2TT, UK

Received December 30, 2001; Revised March 11, 2002; Accepted April 19, 2002

ABSTRACT

MelR is an Escherichia coli transcription factor belonging to the AraC family. It activates expression of the melAB operon in response to melibiose. Full-length MelR (MelR303) binds to two pairs of sites upstream of the melAB transcription start site, denoted sites 1' and 1 and sites 2 and 2', and to a fifth site, R, which overlaps the divergent melR promoter. The C-terminal domain of MelR (MelR173) does not activate transcription. Here we show that, like MelR303, when MelR173 binds to sites 1 and 2 it recruits CRP to bind between these sites. Hence, the C-terminal domain is involved in heterologous interactions. MelR173 binds to the R site, which has 11 of 18 bp identical to sites 1 and 2 but, surprisingly, does not bind to site 1', which has 12 of 18 bp identical, nor to site 2'. Using electrophoretic mobility shift assays, we show that the binding of MelR303 to sites 1' and 2' is due to cooperative binding with the adjacent site. This homologous cooperativity requires the N-terminal domain of the protein. Activation of the melAB promoter requires MelR to occupy site 2', which overlaps the –35 hexamer. Hence, both domains of MelR are required for transcription activation.

INTRODUCTION

The MelR protein of Escherichia coli is a transcription activator required for the metabolism of the disaccharide melibiose (1). MelR activates expression of the melA and melB genes, encoding an α-galactosidase and a melibiose permease, respectively. These genes are co-transcribed from a single promoter, pmelAB, which is 234 bp from the divergent melR promoter, pmelR (Fig. 1). Transcription from pmelAB is totally dependent on MelR and the presence of melibiose in the medium (2), while transcription from pmelR depends on the global transcription activator, the cyclic AMP receptor protein (CRP) (3).

MelR is a member of the AraC family of transcription activators. Members of this family are found in a large number of different bacterial species (reviewed in 4,5). There are more than 100 proteins in this group, including MarA, Rob, SoxS, RhaR, XylS and the virulence protein VirF. Many of the proteins in this family contain ~300 amino acids, with a C-terminal, DNA-binding domain of ~120 amino acids and an N-terminal domain that binds a small ligand activator. The DNA-binding domains of these proteins show substantial similarity and are presumed to share a common tertiary structure, however, the N-terminal domains vary considerably. The structure of MarA, a 129 amino acid activator, which only contains the C-terminal homologous region of the protein, has been determined bound to DNA (6). It contains seven helices with two helix–turn–helix motifs bound to two adjacent major grooves of 16 bp DNA, bending it by 27°. The structure of Rob, another family member where the DNA-binding domain is in the N-terminal part of the protein, has also been determined bound to a DNA target (7). The structures of the DNA-binding domains of Rob and MarA are superimposable with a root mean squared deviation of only 0.9 Å for all main chain atoms. However, in Rob only one of the two helix–turn–helix motifs binds to the major groove of the DNA, the other is free in solution. The structure of the N-terminal domain of AraC has also been determined (8). It contains a β-barrel that binds the sugar and three α-helices, two of which form an antiparallel four-helix bundle with a second domain, giving a dimer.

Transcription activation by AraC has been studied intensively (reviewed in 9,10) and serves as a model for activation by other proteins of the family. AraC is the activator of the ara regulon that is essential for arabinose transport and metabolism. In the absence of the sugar arabinose, it binds to two 16 bp sites (denoted O2 and I1) 200 bp apart at the araBAD promoter, forming a repression loop. In the presence of arabinose, AraC binds to I2, which is adjacent to I1, rather than to O2. This breaks the repression loop and the presence of the activator at I2, next to the RNA polymerase, activates transcription. AraC-dependent transcription initiation at the araBAD promoter is increased by CRP, which binds to a single DNA site upstream of I1 and I2 (11).

In previous work, we have shown that MelR binds to two identical 18 bp sites upstream of pmelAB (named sites 1 and 2) in both the presence and absence of melibiose (12,13). Site 1 is centred between base pairs 100 and 101 upstream of the melAB transcription start site (i.e. at position –100.5), while site 2 is centered at position –63.5. These sites form a perfect inverted repeat, separated by 20 bp. We also showed that a C-terminal fragment of MelR (MelR173) binds to the same two sites (14). Both full-length MelR (MelR303) and MelR173 bend DNA at sites 1 and 2 to similar extents (15). However, in contrast to the C-terminal domains of AraC (16) and XylS (17) or the small MarA and SoxS proteins (18), MelR173 does not activate transcription (14).

Recently we have shown that there are three additional binding sites for MelR in the intergenic region between pmelAB and pmelR. At the pmelR promoter, MelR binds at site R,
MATERIALS AND METHODS

Bacterial strains, plasmids and oligonucleotides

Standard methods for recombinant DNA manipulations were used throughout this work (22). The bacterial strains, plasmids and DNA fragments used are listed in Table 1.

Construction of KK98, KK99, KK100 and VH101

A series of DNA fragments were constructed containing site 2 of pmelAB and a second DNA binding site for MelR, increasingly like site 2, in an 18–2–18 bp arrangement (Figs 1 and 2). The starting DNA was KK43, which contains sites 1’, 1, 2 and 2’ of pmelAB on an EcoRI–HindIII fragment (12). It also contains two PstI sites, one at –23 of pmelAB and the second as part of a Sall–PstI–HindIII linker (from pUC9). The site in the linker was destroyed by PCR mutagenesis, using the oligodeoxynucleotide primer D14314 and a primer upstream of the EcoRI site. D14314 covers the HindIII site and replaces CTGCAG of the PstI site with ATGCAG. This leaves a unique PstI site at position –23 of pmelAB.

\[ \text{HindIII} \quad \text{Sall} \quad \text{melA} \]

D14314: 5’-GC\text{AACGCTTATGCAACCAGCGGTTCGCTCGA}-3’

Initially, pUC9 containing the modified EcoRI–HindIII KK43 insert was cut with EcoRI and PstI to remove pmelAB sequences upstream of –23. The two 18 bp sites in pmelAB were then constructed in two halves using a series of oligodeoxynucleotides on NsI–PstI fragments for the downstream site or on EcoRI–NsI fragments for the upstream half.

For the downstream site of pmelAB, pairs of complementary oligodeoxynucleotides containing the following sequences were synthesized, annealed and cloned into the pUC9 vector. This gave constructs containing different 18 bp sequences upstream of position –23 of pmelAB flanked upstream by an EcoRI–BglII–NsI linker. These sequences corresponded to the 2’ site sequence in KK98, the 1’ site sequence in KK99 and the 1 (or identical 2) site sequence in KK100 (underlined).

KK98

\[ \text{EcoRI} \quad \text{NsI Site 2’} \quad \text{PstI} \]

(G) A\text{ATTCAGATCTATGCAACCAGCGGTTCGCTCGA} (G)

KK99

\[ \text{EcoRI} \quad \text{NsI Site 1’} \quad \text{PstI} \]

(G) A\text{ATTCAGATCTATGCAACCAGCGGTTCGCTCGA} (G)

KK100

\[ \text{EcoRI} \quad \text{NsI Site 2} \quad \text{PstI} \]

(G) A\text{ATTCAGATCTATGCAACCAGCGGTTCGCTCGA} (G)

The upstream DNA binding site for MelR in the KK98, KK99 and KK100 fragments, site 2, was amplified as an EcoRI–NsI fragment using the following primers with KK43 as template:

\[ \text{EcoRI} \quad \text{Site 2} \]

Upstream: 5’-G\text{CAGATCTATGCAACCAGCGGTTCGCTCGA}-3’

Downstream: 5’-G\text{CAGATCTATGCAACCAGCGGTTCGCTCGA}-3’

NsI Site 2

This corresponds to the sequence –73 to –51 of pmelAB between two linkers. This fragment was inserted between the EcoRI and NsI sites flanking the downstream half-sites to give KK98, KK99 and KK100, containing two DNA binding sites for MelR organised in an 18–2–18 bp inverted repeat with a central NsI site.
Table 1. Bacterial strains, DNA fragments and plasmids used in this work

<table>
<thead>
<tr>
<th>Escherichia coli strains</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>BL21 (λDE3)</td>
<td>T7RNAPol+ F− ompT Trp− mB−</td>
</tr>
<tr>
<td>WAM131</td>
<td>ΔlacU169 melR+</td>
</tr>
<tr>
<td>WAM132</td>
<td>ΔlacU169 ΔmelR</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DNA fragments</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>KK39 DNA fragment containing pmelAB sequences bounded by an EcoRI site at −188 and a SalI−PstI−HindIII linker at +21</td>
<td>20</td>
</tr>
<tr>
<td>KK43 DNA fragment containing pmelAB sequences bounded by an EcoRI site at −136 and a SalI−PstI−HindIII linker at +21</td>
<td>12</td>
</tr>
<tr>
<td>The KK43 fragment carries a GC→AT transversion at −73, creating a unique BglII site between MelR-binding sites 1 and 2</td>
<td></td>
</tr>
<tr>
<td>KK81 DNA fragment carrying the intergenic region between pmelAB and pmelR bounded by an EcoRI site at position −312 and a SalI−PstI−HindIII linker at position +21 with respect to the melAB transcription start site</td>
<td>20</td>
</tr>
<tr>
<td>KK98 DNA fragment containing pmelAB sequences from −73 to +21, bounded by an EcoRI site and a SalI−HindIII linker. The fragment contains a 2 bp mutation at −52 and −53 to give an NsiI site between sites 2 and 2′</td>
<td>This work</td>
</tr>
<tr>
<td>KK99 DNA fragment based on KK98, with further mutations in site 2′ to give a fragment containing sites 2 and 1′ in an 18–2–18 bp repeat</td>
<td>This work</td>
</tr>
<tr>
<td>KK100 DNA fragment based on KK98, with further mutations in site 2′ to give a fragment containing two copies of site 2 in an inverted repeat, separated by 2 bp</td>
<td>This work</td>
</tr>
<tr>
<td>TB10 DNA fragment carrying pmelR sequences bounded by an EcoRI site at position −289 and HindIII site at position −136 with respect to the melAB transcription start site</td>
<td>This work</td>
</tr>
<tr>
<td>VH101 DNA fragment based on KK98, with further mutations in site 2 to give a fragment containing sites 1′ and 2′ in an 18–2–18 bp repeat</td>
<td>This work</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Plasmids</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>pAA121 pBR322 derivative for cloning EcoRI−HindIII fragments</td>
<td>35</td>
</tr>
<tr>
<td>pCM117−173 pET9d derivative encoding MelR173 on an NcoI−BamHI fragment under the control of a T7 promoter</td>
<td>14</td>
</tr>
<tr>
<td>pCM117−303 pET9d derivative encoding full-length MelR on an NcoI−BamHI fragment under the control of a T7 promoter</td>
<td>14</td>
</tr>
<tr>
<td>pCM118−173 pBR322 derivative encoding MelR173 under the control of the CRP-independent galP2 promoter</td>
<td>14</td>
</tr>
<tr>
<td>pCM118−314 pBR322 derivative encoding full-length MelR with a N-terminal 11 amino acid fusion under the control of the CRP-independent galP2 promoter</td>
<td>14</td>
</tr>
<tr>
<td>pJW15 pAA121 derivative carrying the melR gene expressed from its own promoter</td>
<td>30</td>
</tr>
<tr>
<td>pLysS pACYC184 derivative which supplies low levels of T7 lysozyme</td>
<td>23</td>
</tr>
<tr>
<td>pRW50 Low copy number lac expression vector, also encoding resistance to tetracycline</td>
<td>28</td>
</tr>
<tr>
<td>pVH−173 pET9d derivative encoding MelR173 with an additional N-terminal His6 tag on an NsiI−BamHI fragment under the control of a T7 promoter</td>
<td>This work</td>
</tr>
</tbody>
</table>

*Figure 2.* Sequences of the MelR-binding sites in the melR and melAB intergenic regions. The sequences are written in the orientation of site 2. Bases identical to sites 1 and 2 are in bold.

| Site 1, 2 | ATCTGAATTATGGAATT |
| Site 1′ | CTCTGCTTTTCCGGAAT |
| Site 2′ | CTCGGCTTCCCAGTTGA |
| Site R | TCTGATATCCAGGAA |

*HindIII primer: 5′-AGCAAGCTTCCGCTGCTGCACTAAAA-3′*

*EcoRI primer: 5′-GCAAGAATTCCTCTAGATCTCGGA-3′*

This resulted in an EcoRI−HindIII fragment carrying pmelR with the EcoRI site upstream of the pmelR DNA site for CRP and the HindIII site downstream of the melR translation initiation codon (−289 to −136 with respect to the pmelAB initiation start site).

**Construction of pVH−173**

The plasmid pVH−173, encoding MelR173 with a His6 tag at the N-terminus, was constructed from pCM118−173 (14), a pET9d derivative containing DNA encoding the last 173 amino acids of MelR between NcoI and BamHI sites. To do this, complementary oligodeoxynucleotides containing the sequence

| NsiI | NcoI |
| 5′-CATGATCACACACCACACACCACACT-3′ |

were annealed. These form a linker containing a NsiI site and a NcoI site flanking DNA encoding a hexahistidine linker (underlined). Plasmid pCM118−173 was restricted with NcoI and ligated to the linker. The resulting DNA was transformed

**Construction of TB10**

This was done by PCR mutagenesis using KK81 (20) cloned in pAA121 as a template and the following primers.

**Figure 2.** Sequences of the MelR-binding sites in the melR and melAB intergenic regions. The sequences are written in the orientation of site 2. Bases identical to sites 1 and 2 are in bold.
into *E. coli* and the resulting colonies tested for the presence of the additional *Nsi*I site in the plasmid. The orientation of the linker was determined by examining the length of the small *Xho*I–*Nsi*I fragment in the plasmid. Finally, the insert was sequenced to confirm the orientation of the linker and the initiation codon of MelR173.

**Preparation of pure proteins**

MelR303 was overexpressed in *E. coli* strain BL2I(λDE3) [pLysS] (23) transformed with the T7 expression plasmid pCM117–303 (14), as described (20). Traces of nucleases left after the heparin–agarose column were removed by passing the protein through an additional Q-Sepharose column equilibrated in 20 mM Tris–HCl pH 7.0, 0.1 mM EDTA, 20% (v/v) glycerol, 10 mg/l phenylmethylsulphonyl fluoride (PMSF), 0.1 mM dithiothreitol (DTT), 300 mM NaCl.

MelR173 was overexpressed in *E. coli* strain BL2I(λDE3) [pLysS] transformed with pVH-173. The cells were grown in luria broth. Protein expression was induced by addition of 1 mM isopropyl β-D-thiogalactoside, at a cell density giving an A₅₆₀ of ~0.5, and the cells were harvested by centrifugation 4 h after induction. The expressed protein was found to be in inclusion bodies. It was purified on a nickel–agarose column, after denaturation in guanidine hydrochloride, as described for MarA (24). Fractions containing MelR173 were diluted 4-fold to reduce the NaCl concentration, loaded onto a heparin–agarose column and eluted with a 250 mM–1 M NaCl gradient in 50 mM sodium phosphate buffer, pH 7.6, 20% glycerol, 0.5 mM EDTA, 10 mg/l PMSF. The purified MelR173 protein eluted at ~700 mM NaCl. It was stored at ~20°C. Comparison of electrophoretic mobility shift assay (EMSA) and DNase I footprints, using crude cell extracts containing MelR173 expressed from pCM117–173 (without the His tag and without denaturation) with protein purified as above, confirmed that the DNA binding specificity is not affected by the His tag or the purification method. This is in agreement with similar experiments on full-length MelR303 (25).

Protein concentrations were determined either from Bradford assays, calibrated with bovine serum albumin (BSA) (26) or from the absorbance at 280 nm using the equation (27):

$$
ε_{280} = \text{(no. of Trp} \times 5500) + \text{(no. of Tyr} \times 1490).
$$

For MelR303 $ε_{280} = 42 400 \text{ M}^{-1} \text{ cm}^{-1}$, while for MelR173 $ε_{280} = 21 430 \text{ M}^{-1} \text{ cm}^{-1}$.

**Measurement of promoter activities in vivo**

DNA fragments containing the *melAB* or *melR* promoters were cloned into pRW50, a low copy number vector (28), to give promoter::lac fusions. The activity of the enzyme β-galactosidase in cells carrying these recombinants was measured by the Miller method (29). Cells were grown in minimal media with fructose as the carbon source, either with or without melibiose, as in our previous work (1). Assays were performed in isogenic *melR*⁺ (WAM131) or ΔmelR (WAM132) strains (20).

**DNase I footprints**

DNase I footprinting experiments were performed as in our previous work (20). Incubations contained 4–10 nM purified KK39 EcoRI–HindIII fragment (20) that had been specifically labelled at the HindIII end with $[^γ^{32}]P$ATP and polynucleotide kinase. Incubations contained 10 mM melibiose, 1.2 μM MelR303, 11 μM MelR173 and 75 nM CRP as indicated. After DNase I treatment, footprint patterns were analysed on polyacrylamide sequencing gels that were calibrated with Maxam–Gilbert sequence ladders.

**EMSA**

For the titration experiments, the *EcoRI–HindIII* fragments carrying MelR-binding sites were purified, end-labelled using [α-$^{32}$P]dATP and the Klenow fragment of DNA polymerase and used in gel retardation assays as in our previous work (30). Binding assays were done in 30 μl of buffer containing 40 mM Tris–HCl pH 8.0, 100 mM KCl, 50 mM NaCl, 0.5 mM EDTA, 0.5 mM DTT, 0.1 mg/ml BSA, 5 μg/ml herring sperm DNA. No difference was observed for gels run in the presence or absence of melibiose. For quantitative studies on fragments containing two DNA binding sites, eight or 16 samples with 0–2 μM protein were run in parallel on separate lanes. Up to three bands of radioactivity were observed in each lane, corresponding to the free DNA, a retarded band and a second, more retarded band. The amount of radioactivity in each band was determined using a phosphorimager plate, measuring the intensity using ImageQuant 3.3 (Molecular Dynamics). The fraction of the total radioactivity found in each band was fitted to the equations below (31) using non-linear regression in SigmaPlot (SPSS Inc.).

$$
F_{\text{free}} = 1/Z
$$

$$
F_1 = K_1 [P]/Z
$$

$$
F_2 = K_2 [P]^2/Z
$$

$$
Z = 1 + K_1 [P] + K_2 [P]^2
$$

where $F_{\text{free}}$ is the fraction of DNA species in the free band, $F_1$ is the fraction of DNA species in the first retarded band and $F_2$ is the fraction of DNA species in the second, more retarded band. [P] is the protein concentration in subunits (we have assumed that a monomer binds to each site; the degree of cooperativity is not affected by this assumption). $K_1$ is the macroscopic association constant for a single protein molecule binding to the DNA. $K_2$ is the macroscopic association constant for two protein molecules binding simultaneously to free DNA.

The (macroscopic) constants $K_1$ and $K_2$ are related to the (microscopic) association constants for binding to two individual sites A and B on the DNA as below.

$$
K_1 = k_A + k_B
$$

$$
K_2 = k_A k_B k_{AB}
$$

where $k_A$ is the association constant for site A, $k_B$ is the association constant for site B and $k_{AB}$ is the cooperativity factor between site A and site B, i.e. the degree to which binding to both sites is influenced by the neighbouring site.

When different protein preparations were used, the relative affinities of the pairs of fragments remained the same, as did the ratios of $K_1/K_2$, but the absolute values differed, presumably due to different specific activities of the preparations. For these reasons it is not possible to compare binding constants for a given DNA sequence between proteins or between preparations, just the relative affinities of different DNA sequences for the same protein and the cooperativity values.
Table 2. In vivo activities of pmeAB::lac fusions in pRW50 in E. coli strains WAM131 (∆lacU169) and WAM132 (∆lacU169 ∆melR)

<table>
<thead>
<tr>
<th>Plasmid</th>
<th>β-Galactosidase activity of KK43 [Miller units (29)]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>WAM132 (∆melR host)</td>
</tr>
<tr>
<td></td>
<td>−melibiose +melibiose Fold induction −melibiose +melibiose Fold induction</td>
</tr>
<tr>
<td>pAA121</td>
<td>4 1.8 0.5 2.7 188 70</td>
</tr>
<tr>
<td>pJW15</td>
<td>9 1581 175 30 1431 47</td>
</tr>
<tr>
<td>pCM118–314</td>
<td>6 1377 229 6 1367 227</td>
</tr>
<tr>
<td>pCM118–173</td>
<td>2.5 2.8 1.0 3 2 0.7</td>
</tr>
</tbody>
</table>

β-Galactosidase levels in two strains of E. coli containing pmeAB::lac fusions in pRW50 are shown. The promoter fragment used was KK43 containing sites 1′, 1, 2 and 2′. Cells were grown ± melibiose. Cells also contained multicopy plasmids expressing full-length MelR (pJW15, pCM118–314), N-terminally truncated MelR173 (pCM118–173) or a control (pAA121). Assays were performed as in Webster et al. (1). Assays vary by <10% when repeated independently.

Table 3. In vivo activities of pmeIR::lac fusions in pRW50 in E. coli strain WAM132 (∆lacU169 ∆melR) (19)

<table>
<thead>
<tr>
<th>Plasmid</th>
<th>β-Galactosidase activity of TB10 [Miller units (29)]</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>−melibiose Relative activity +melibiose Relative activity</td>
</tr>
<tr>
<td>pAA121</td>
<td>235 100% 243 100%</td>
</tr>
<tr>
<td>pJW15</td>
<td>149 63% 107 44%</td>
</tr>
<tr>
<td>pCM118–314</td>
<td>74 32% 61 25%</td>
</tr>
<tr>
<td>pCM118–173</td>
<td>57 24% 54 22%</td>
</tr>
</tbody>
</table>

β-Galactosidase levels in E. coli containing pmeIR::lac fusions in pRW50 are shown. The promoter fragment used was TB10. Cells were grown ± melibiose. Cells also contained multicopy plasmids expressing full-length MelR (pJW15, pCM118–314), N-terminally truncated MelR173 (pCM118–173) or a control (pAA121). Assays were performed as in Webster et al. (1). Assays vary by <10% when repeated independently.

RESULTS

In vivo transcription

To examine the effect of the C-terminal domain of MelR on transcription in vivo, we used derivatives of the lac expression vector pRW50 (28) carrying pmeAB::lac (12) and pmeIR::lac fusions (Tables 2 and 3). Expression of β-galactosidase from the plasmids was measured in the WAM132 (∆melRΔlac) strain of E. coli (20) grown in the presence or absence of melibiose. Either MelR303 or MelR173 was expressed in this strain from a second plasmid in trans. For pmeAB, expression was also tested in the parent WAM131 melR⁺Δlac strain (20).

For pmeAB in the absence of melibiose, very little expression of lacZ is observed in either the melR⁺ or ∆melR strain (Table 2). In the ∆melR strain, in the presence of melibiose, β-galactosidase is expressed from pmeAB in the presence of pJW15 and pCM118–314, carrying melR (see Table 1), but not in the presence of pCM118–173, carrying melR173. In the melR⁺ strain, expression of β-galactosidase from pmeAB is induced by melibiose and this is increased by the presence of multicopy plasmids pJW15 and pCM118–314, carrying melR. However, the presence of pCM118–173, carrying melR173, severely reduces expression from pmeAB. This is in accordance with our previous studies, in a different strain of E. coli, showing that transcription of pmeAB requires both MelR303 and melibiose and that MelR173 does not activate the promoter but acts as a trans-dominant repressor (2,14).

At the pmeIR promoter, expression is dependent on CRP (3), so lacZ cloned under pmeIR is expressed in the ∆melR strain in the absence of MelR303 and MelR173 (Table 3). However, less expression is observed in the presence of plasmids carrying either full-length melR or melR173, i.e. both proteins repress expression from pmeIR. This repression occurs both in the presence and absence of melibiose.

DNase I footprinting

DNase I footprinting experiments were used to examine the binding of full-length MelR303 and MelR173 at pmeAB. Figure 3 shows that, as expected, MelR303 protects sites 1′, 1 and 2 from DNase I cleavage, both in the absence (lane g) and presence (lane f) of melibiose. In the presence of melibiose (Fig. 3, lane f), additional weak protection is observed at site 2′. When CRP is added (Fig. 3, lane e), the protection at site 2′ is more pronounced, and strong additional protection is observed between sites 1 and 2. This is in agreement with our previous results showing that CRP binds cooperatively with MelR between sites 1 and 2, enhancing occupation of site 2′ (20,21). MelR173 protects sites 1 and 2 from DNase I cleavage (Fig. 3, lanes c and d) but, in contrast to MelR303, there is no protection of sites 1′ or 2′ either in the presence or absence of melibiose. Addition of CRP in the presence of MelR173 causes protection of DNA between sites 1 and 2 and increases the protection at sites 1 and 2, but does not extend the footprint at site 1′ or 2′ (Fig. 3, lane b). Parallel DNase I footprinting experiments at pmeIR show that MelR303 and MelR173 each protect site R from cleavage (data not shown).

EMSA

The above results show that, while MelR303 can bind to all five previously identified sites in the pmeIR–pmeAB intergenic region, MelR173 only binds to the two identical sites, sites 1 and 2, and to site R. MelR173 is unable to occupy site 1′ or 2′ at pmeAB. One explanation for this could be that the differences in the sequences between sites 1′ and 2′ and sites 1 and 2 (Fig. 2) prevent MelR173 from binding to the former sites. Alternatively, the small 2 bp spacing between sites 1′ and 1 (and 2′ and 2) may prevent two molecules of MelR173 from binding simultaneously to the 18–2–18 bp repeat. To distinguish between these possibilities, we constructed a series of DNA fragments, KK98, KK99 and KK100, each containing two MelR-binding sites; a constant site with the sequence of site 2 and a second site, 2 bp away, increasingly close in sequence to site 2 (Fig. 1). The KK98 fragment contains the sequences of
reaction (lane m) with the KK39 EcoRI–HindIII fragment containing DNA cleavage due to attack by DNase I was analysed. The DNA was labelled on the promoter template strand at the melAB transcript start point as +1. The locations of the different MelR- and CRP-binding sites are indicated as vertical arrows or boxes as in Figure 1.

Figure 3. DNase I footprint analysis of MelR and CRP binding to melAB DNA. The figure shows an autoradiogram of a polyacrylamide sequencing gel on which DNA cleavage due to attack by DNase I was analysed. The DNA was the KK39 EcoRI–HindIII fragment containing the melAB promoter specifically labelled on the promoter template strand at the HindIII end. Prior to DNase I treatment, the labelled DNA was preincubated with melibiose, MelR303, MelR173, CRP and cAMP as indicated. The gel is calibrated with a Maxam–Gilbert G+A reaction (lane m) with the melAB transcript start point as +1. The locations of the different MelR- and CRP-binding sites are indicated as vertical arrows or boxes as in Figure 1.

We then examined binding of purified MelR303 and MelR173 to the DNA fragment, VH101, containing the site 1 sequence in KK98 with site 2 sequence in TK99. For the KK98 fragment, MelR303 gives a single band of lower mobility than free DNA, with a second band of weak intensity only observed at high protein concentrations of Mel. In the KK100 fragment, two bands of lower mobility than free DNA are observed, the second one being more intense than the lower one at medium protein concentrations. With the KK100 DNA fragment, the most retarded band is much more intense than the lower retarded band even at the lowest protein concentration. The relative macroscopic association constants to pairs of fragments were measured as described for MelR173 (Table 5). These show that K1 is similar for the KK98 and KK99 DNA fragments and about half that for the KK100 fragment, suggesting that this again is approximately equal to the affinity of binding to site 2. For the KK100 fragment, K2 is much larger than expected by independent binding to two sites, giving about a 30-fold cooperativity for binding to both sites (Table 5).

To examine the cooperativity of MelR303 binding further, a DNA fragment, VH101, containing the site 1′ sequence next to site 2′, was constructed by replacing the consensus site 2′ sequence in KK98 with site 1′. No binding of MelR303 to this fragment was observed even at the highest protein concentration tested, 64 μM (data not shown). This shows that binding of MelR303 to site 1′ or 2′ alone is extremely weak. The binding of MelR to these sites in the KK98 and KK99 DNA fragments must therefore be due primarily to cooperative binding with MelR303 bound at the adjacent consensus sites. Independent experiments show that if site 2 is mutated no binding is seen in a fragment containing sites 2 and 2′ (32).

We also examined binding of both MelR303 and MelR173 to the R site, in fragment TB10 (Fig. 5). Both proteins bind to this DNA fragment in a similar way to their binding to the KK98 fragment; MelR303 gives two bands of lower mobility than the free DNA, with the second band filling at high protein concentrations, but MelR173 gives only a single band. Comparison of the binding of MelR to the KK98 and TB10 DNA fragments on the same gel gives similar values of K1 and K2 for MelR303 for both fragments, showing that they have similar affinity, while MelR173 binds slightly less tightly to the TB10 fragment.

**DISCUSSION**

To better understand the molecular mechanisms of transcription activation at melAB, we have compared binding of the full-length
MelR transcription activator, MelR303, to that of its C-terminal domain, MelR173, which does not activate transcription, using DNase I footprinting and EMSA. The footprinting studies in this paper show that the C-terminal domain of MelR, MelR173, binds to sites 1, 2 and R in the same way as the full-length MelR303, protecting the same base pairs. Our previous studies showed that both proteins bend the DNA at site 1 or 2 to a similar extent (15). This suggests that the interactions of the two proteins with DNA are similar and so require solely the C-terminal domain of MelR. The footprinting study also shows that MelR173, when bound at sites 1 and 2, is sufficient to recruit CRP to pmelAB, between sites 1 and 2. This site contains only a few bases in common with a consensus CRP site. We have recently shown that binding of CRP and MelR are cooperative, involving protein–protein contacts (21). These heterologous contacts must occur with the C-terminal domain of MelR.

The footprinting studies on the KK39 DNA fragment and the EMSAs show that MelR173 cannot bind to site 2' or 1'. MelR173 binds independently to the two identical sites in the

**Table 4.** Relative association constants from EMSA of MelR173 with different DNA fragments

<table>
<thead>
<tr>
<th>DNA fragment</th>
<th>$K_1$ ($10^6$ M)</th>
<th>$K_2$ ($10^{12}$ M$^2$)</th>
<th>$k_A$ ($10^6$ M)</th>
<th>$k_B$ ($10^6$ M)</th>
<th>$k_{AB}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>KK98</td>
<td>7 ± 0.73</td>
<td>0</td>
<td>7</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>KK99</td>
<td>8.2 ± 0.8</td>
<td>0</td>
<td>8.2</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>KK100</td>
<td>17 ± 1.8</td>
<td>65 ± 15</td>
<td>8.5</td>
<td>8.5</td>
<td>0.9</td>
</tr>
</tbody>
</table>

The $K_1$ and $K_2$ values are the macroscopic association constants from several gels with the data fitted simultaneously in Sigmaplot. From these $K_1$ and $K_2$ values, the microscopic association constants for binding to individual sites, $k_A$ and $k_B$, and the cooperativity constant, $k_{AB}$, have been estimated for the KK100 DNA fragment with two equivalent sites, assuming that $k_A$ and $k_B$ are identical. For the KK98 and KK99 fragments, $k_A$ is assumed to be equal to $K_1$. The errors shown are those from the fit, which are similar to those obtained from fitting data from each gel individually for a given protein preparation. When different protein preparations were used the relative affinities of the pairs of fragments remained the same, as did the ratios of $K_1/K_2$, but the absolute values differed, presumably due to different specific activities of the preparations.


Table 5. Relative association constants from EMSA of MelR303 with different DNA fragments

<table>
<thead>
<tr>
<th>DNA fragment</th>
<th>$K_1 (10^{9} \text{ M}^{-1})$</th>
<th>$K_2 (10^{12} \text{ M}^{-2})$</th>
<th>$k_1 (10^5 \text{ M}^{-1})$</th>
<th>$k_2 (10^9 \text{ M})$</th>
<th>$k_{AB}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>KK98</td>
<td>1.2 ± 0.3</td>
<td>19 ± 2.2</td>
<td>1.25</td>
<td>n.d.</td>
<td>n.d.</td>
</tr>
<tr>
<td>KK99</td>
<td>2.5 ± 0.3</td>
<td>46 ± 9</td>
<td>1.25</td>
<td>1.25</td>
<td>31</td>
</tr>
</tbody>
</table>

The $K_1$ and $K_2$ values are the macroscopic association constants from several gels with the data fitted simultaneously in Sigmaplot. From these $K_1$ and $K_2$ values, the microscopic association constants for binding to individual sites, $k_{1A}$ and $k_{2B}$, and the cooperativity constant, $k_{AB}$, have been estimated for the KK100 DNA fragment with two equivalent sites, assuming that $k_1$ and $k_2$ are identical. For the KK98 and KK99 fragments, $k_A$ is assumed to be the same as for KK100 with MelR303. The errors shown are those from the fit, which are similar to those obtained from fitting data from each gel individually for a given protein preparation. When different protein preparations were used the relative affinities of the pairs of fragments remained the same, as did the ratios of $K_1/K_2$, but the absolute values differed, presumably due to different specific activities of the preparations. The values of the association constants for this preparation are much lower than for the one used in Figures 4 and 5. n.d., not determined.

![Figure 5. EMSA of MelR173 and MelR303 binding to the TB10 fragment containing site R. The figure shows autoradiograms of EMSAs performed with labelled TB10 DNA fragments carrying the R site, with either MelR173 (A) or MelR303 (B). MelR173 concentrations: lane 1, 0 nM; lane 2, 22 nM; lane 3, 44 nM; lane 4, 88 nM. MelR303 concentrations: lane 1, 0 nM; lane 2, 6.7 nM; lane 3, 20 nM; lane 4, 34 nM.](image)

KK100 fragment, showing that it can bind to two adjacent sites, but it does not bind to sites 1' and 2' in the KK98 or KK99 fragments. In contrast, MelR303 binds the adjacent sites in the KK100 DNA fragment with high cooperativity. It binds site 2' or 1' in the KK98 and KK99 fragments, where there is an adjacent site 2, but it does not bind to the VH101 fragment with site 1' adjacent to site 2', i.e. in the absence of site 2. This shows that binding of MelR303 at sites 1' and 2' in KK98 and KK99 is due solely to the cooperativity of binding with the adjacent site 2 and that this cooperativity requires the N-terminal domain of MelR. The difference in cooperativity between MelR303 and MelR173 is also seen at the R site in TB10. The DNA sequence adjacent to the R site bears little resemblance to site 2, yet MelR303 gives two retarded bands in EMSA, while MelR173 gives only one, with similar affinity to the KK98 fragment. Our interpretation of the more retarded band is that MelR303, once bound at a target site, binds weakly to the adjacent DNA due to its highly cooperative DNA binding. As the protein–DNA interactions appear to be identical in both MelR173 and MelR303, cooperativity of binding to the adjacent DNA sites is probably due to protein–protein interactions involving the N-terminal domain of MelR. These findings have important implications with respect both to the DNA specificity of MelR and its mode of transcription activation.

The binding of MelR173 and MelR303 to site R in the TB10 fragment but not to an isolated site 1' in VH101 suggests that the R site is a stronger binding site than site 1'. However, the R site only contains 11 of 18 bp in common with site 2, while site 1' contains 12 of 18 bp identical (Fig. 2). This suggests that the bases in site R that are the same as in site 2 but not conserved in site 1', i.e. A6 and G15, are more important for binding MelR than those changed at site R, i.e. T8, G13 and T18. Mutational studies of the DNA-binding site of AraC (33) showed that two groups of bases, 8 bp apart, termed the A and B boxes, are important for protein binding. The crystal structure of MarA with its cognate sequence (6) shows direct hydrogen bond contacts to two groups of bases 9 bp apart, the equivalent of the A and B boxes. One group of 3 bp contact one helix–turn–helix and the other group of 2 bp contact the other helix–turn–helix motif. Our results suggest that A6 and G15 may be part of the A box and B box elements for MelR while T8, G13 and T18 may lie outside these contact sites. Further studies to define the DNA binding site for MelR are underway.

The current studies support our previous suggestion that transcription activation at pmelAB requires the binding of MelR to site 2', which overlaps the –35 sequence of the promoter (20). The requirement of cooperative binding of MelR at sites 2 and 2' explains the trans-dominant negative effect of MelR173 at pmelAB, despite the inability of MelR173 to bind to the critical site 2'. MelR173 competes with MelR303 binding to site 2 and, hence, prevents the binding of MelR303 to site 2'. The inability of MelR173 to bind to site 2' explains in part why MelR173 cannot activate transcription. The N-terminal domain is required for cooperativity while the C-terminal domain is required for DNA binding, hence, both domains are required for transcription activation of pmelAB.

Surprisingly, the optimal MelR-binding sites are not optimal for transcription activation. Base pairs –34 and –37 are critical for transcription, yet differ from site 2 (34). When these bases are retained, transcription activation by MelR303 is increased if site 2' is changed to resemble the site 1/site 2 sequence, but is much more markedly increased with the sequence of site 1'. In both cases activation is still dependent on melibiose (20) and neither of these improved promoters is activated by MelR173 (data not shown). Hence, DNA binding is necessary but not sufficient for transcription activation.
The fact that a poor binding site at −35 enhances transcription activation by MelR emphasises the importance of the cooperative interactions between MelR proteins at adjacent sites in pmelAB. In addition to these interactions, cooperative binding of MelR with CRP also enhances transcription activation (20,21). Our studies show that both domains of MelR are involved in cooperative interactions; the C-terminal domain in interactions with CRP, while the N-terminal domain is required for interactions between MelR proteins. Cooperative binding of one or more regulatory proteins to a series of DNA binding sites at a promoter is found in many genomes. In such cases, at pMelAB, the critical site for activation must be the weakest site, which is filled last as a result of the cooperative interactions.

ACKNOWLEDGEMENTS

We thank Rosemary A. Parslow for skilful purification of MelR and Christine L. Webster for promoter assays in vivo. This study was funded with a BBSRC project grant and a BBiSC PhD studentship to V.J.H.

REFERENCES

